Nanomath
Home/AOMM™
Automated Oral Minimal Model Program · v1.3 · 2026

Mechanistic trial readouts from OGTT MMTT runs.

Automated Oral Minimal Model(AOMM™) provides a single, reproducible and validated workflow to calculate model-based and mechanistic metabolic biomarkers in diabetes-metabolism clinical trials and research.

↓Access →Science highlights →Platform highlights
Powered by SAAM II™
Latest
SEP 2026 EASD 2026 Milan — 3 oral presentations Oral presentations
  1. Measurement-driven variability in glycaemic staging may influence disease-modifying treatment eligibility in early stage type 1 diabetes
  2. Measuring the disease, not just risk: Phitotal as a continuous endpoint for stage 1 type 1 diabetes trials
  3. Early beta cell decline in preclinical type 1 diabetes: evidence from the oral minimal model
 JUN 2026 AOMM™ at ADA 2026 — TrialNet poster APR 2026 ATTD Barcelona — AOMM™ presented JUN 2025 ADA 2025 — AOMM™ markers in T2D diet response
AOMM™ platform highlights — OGTT to insulin sensitivity (Si) and β-cell response (Φ)

AOMM Applications

CTR with Min Mod endpoints

Collabs

  • Claudio Cobelli — Padova
  • Colin Dayan — Birmingham
  • Alfonso Galderisi — Yale
  • Joseph Hedrick — C-Path
  • Alice Carr — Alberta
  • Peter Senior — Alberta
  • Breakthrough T1D
  • C-Path & TrialNET
Insulin sensitivity — placebo vs treatment β-cell indices — placebo vs treatment β-cell function — T1D progression Insulin sensitivity — treatment arms

↓Access AOMM™